fospropofol disodium

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Colonoscopy

Conditions

Colonoscopy, Colon Polyps

Trial Timeline

Sep 1, 2004 → Dec 1, 2004

NCT ID

NCT00209573

About fospropofol disodium

fospropofol disodium is a phase 3 stage product being developed by Eisai for Colonoscopy. The current trial status is completed. This product is registered under clinical trial identifier NCT00209573. Target conditions include Colonoscopy, Colon Polyps.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00209599	Phase 2	Terminated	Feb 1, 2005	Mar 1, 2005	Colonoscopy
NCT00209560	Phase 3	Terminated	Oct 1, 2004	Mar 1, 2005	Arthroscopy
NCT00209573	Phase 3	Completed	Sep 1, 2004	Dec 1, 2004	Colonoscopy
NCT00209586	Phase 3	Terminated	Sep 1, 2004	Mar 1, 2005	Flexible Bronchoscopy
NCT00209547	Phase 3	Completed	Feb 1, 2004	Mar 1, 2005	Angioplasty
NCT00209534	Phase 2	Completed	Jan 1, 2003	Feb 1, 2004	Colonoscopy

Competing Products

7 competing products in Colonoscopy

See all competitors

Product	Company	Stage	Hype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCl	Eisai	Phase 2/3	65
fospropofol disodium	Eisai	Phase 2	52
fospropofol disodium	Eisai	Phase 2	52
HSK3486 + Propofol	Haisco Pharmaceutical Group	Phase 2	49
HSK3486 + Propofol	Haisco Pharmaceutical Group	Phase 2	49
Methylene Blue MMX 25 mg modified release tablets	Cosmo Pharmaceuticals	Phase 2	47
Polyethylene glycol 4000 + Macrogol 3350 plus ascorbic acid	Rafael Holdings	Approved	77

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved